{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T15:40:27Z","timestamp":1787586027654,"version":"build-2736575974"},"reference-count":104,"publisher":"Springer Science and Business Media LLC","issue":"4","license":[{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T00:00:00Z","timestamp":1771804800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100001537","name":"University of Auckland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100001537","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1007\/s40265-026-02285-2","type":"journal-article","created":{"date-parts":[[2026,2,23]],"date-time":"2026-02-23T18:13:54Z","timestamp":1771870434000},"page":"465-483","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Developing CRISPR-Based Therapies for Epidermolysis Bullosa: A Comprehensive Review of Current Strategies"],"prefix":"10.1007","volume":"86","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9481-4149","authenticated-orcid":false,"given":"Alex","family":"du Rand","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0000-0320-8569","authenticated-orcid":false,"given":"Ben","family":"Buttle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1147-4618","authenticated-orcid":false,"given":"Hilary","family":"Sheppard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,2,23]]},"reference":[{"issue":"1","key":"2285_CR1","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1038\/s41572-020-0210-0","volume":"6","author":"A Bardhan","year":"2020","unstructured":"Bardhan A, Bruckner-Tuderman L, Chapple ILC, Fine JD, Harper N, Has C, et al. Epidermolysis bullosa. Nat Rev Dis Primers. 2020;6(1):78.","journal-title":"Nat Rev Dis Primers"},{"issue":"3","key":"2285_CR2","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1016\/j.jid.2018.10.017","volume":"139","author":"H Vahidnezhad","year":"2019","unstructured":"Vahidnezhad H, Youssefian L, Saeidian AH, Uitto J. Phenotypic spectrum of epidermolysis bullosa: the paradigm of syndromic versus non-syndromic skin fragility disorders. J Invest Dermatol. 2019;139(3):522\u20137.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2285_CR3","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1080\/14712598.2025.2525860","volume":"25","author":"WM Wang","year":"2025","unstructured":"Wang WM, Feng H, Jia QN, Jin HZ. Treatment progress of inherited epidermolysis bullosa. Expert Opin Biol Ther. 2025;25(8):847\u201357.","journal-title":"Expert Opin Biol Ther"},{"issue":"Suppl 1","key":"2285_CR4","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1007\/s10198-016-0783-4","volume":"17 Suppl 1","author":"A Angelis","year":"2016","unstructured":"Angelis A, Kanavos P, L\u00f3pez-Bastida J, Linertov\u00e1 R, Oliva-Moreno J, Serrano-Aguilar P, et al. Social\/economic costs and health-related quality of life in patients with epidermolysis bullosa in Europe. Eur J Health Econ. 2016;17 Suppl 1(Suppl 1):31\u201342.","journal-title":"Eur J Health Econ"},{"issue":"1","key":"2285_CR5","doi-asserted-by":"publisher","first-page":"367","DOI":"10.1186\/s13023-022-02509-0","volume":"17","author":"JA Feinstein","year":"2022","unstructured":"Feinstein JA, Bruckner AL, Chastek B, Anderson A, Roman J. Clinical characteristics, healthcare use, and annual costs among patients with dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):367.","journal-title":"Orphanet J Rare Dis"},{"issue":"6","key":"2285_CR6","doi-asserted-by":"publisher","first-page":"627","DOI":"10.1007\/s40291-022-00613-2","volume":"26","author":"A du Rand","year":"2022","unstructured":"du Rand A, Hunt JMT, Feisst V, Sheppard HM. Epidermolysis bullosa: a review of the tissue-engineered skin substitutes used to treat wounds. Mol Diagn Ther. 2022;26(6):627\u201343.","journal-title":"Mol Diagn Ther"},{"issue":"7680","key":"2285_CR7","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1038\/nature24487","volume":"551","author":"T Hirsch","year":"2017","unstructured":"Hirsch T, Rothoeft T, Teig N, Bauer JW, Pellegrini G, De Rosa L, et al. Regeneration of the entire human epidermis using transgenic stem cells. Nature. 2017;551(7680):327\u201332.","journal-title":"Nature"},{"issue":"4","key":"2285_CR8","doi-asserted-by":"publisher","first-page":"780","DOI":"10.1038\/s41591-022-01737-y","volume":"28","author":"I Gurevich","year":"2022","unstructured":"Gurevich I, Agarwal P, Zhang P, Dolorito JA, Oliver S, Liu H, et al. In vivo topical gene therapy for recessive dystrophic epidermolysis bullosa: a phase 1 and 2 trial. Nat Med. 2022;28(4):780\u20138.","journal-title":"Nat Med"},{"issue":"4","key":"2285_CR9","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1111\/bjd.18921","volume":"183","author":"C Has","year":"2020","unstructured":"Has C, Bauer JW, Bodemer C, Bolling MC, Bruckner-Tuderman L, Diem A, et al. Consensus reclassification of inherited epidermolysis bullosa and other disorders with skin fragility. Br J Dermatol. 2020;183(4):614\u201327.","journal-title":"Br J Dermatol"},{"issue":"10","key":"2285_CR10","doi-asserted-by":"publisher","first-page":"1176","DOI":"10.1111\/exd.13979","volume":"28","author":"C Prodinger","year":"2019","unstructured":"Prodinger C, Reichelt J, Bauer JW, Laimer M. Epidermolysis bullosa: advances in research and treatment. Exp Dermatol. 2019;28(10):1176\u201389.","journal-title":"Exp Dermatol"},{"issue":"1","key":"2285_CR11","doi-asserted-by":"publisher","first-page":"18","DOI":"10.18699\/VJGB-23-04","volume":"27","author":"YY Kotalevskaya","year":"2023","unstructured":"Kotalevskaya YY, Stepanov VA. Molecular genetic basis of epidermolysis bullosa. Vavilov J Genet Breed. 2023;27(1):18\u201327.","journal-title":"Vavilov J Genet Breed"},{"issue":"1","key":"2285_CR12","doi-asserted-by":"publisher","first-page":"135","DOI":"10.4161\/cam.22418","volume":"7","author":"D Kiritsi","year":"2013","unstructured":"Kiritsi D, Has C, Bruckner-Tuderman L. Laminin 332 in junctional epidermolysis bullosa. Cell Adh Migr. 2013;7(1):135\u201341.","journal-title":"Cell Adh Migr"},{"issue":"5","key":"2285_CR13","doi-asserted-by":"publisher","first-page":"551","DOI":"10.1016\/j.abd.2020.05.001","volume":"95","author":"LM Mariath","year":"2020","unstructured":"Mariath LM, Santin JT, Schuler-Faccini L, Kiszewski AE. Inherited epidermolysis bullosa: update on the clinical and genetic aspects. An Bras Dermatol. 2020;95(5):551\u201369.","journal-title":"An Bras Dermatol"},{"issue":"4","key":"2285_CR14","doi-asserted-by":"publisher","DOI":"10.3390\/ijms25042243","volume":"25","author":"J Bischof","year":"2024","unstructured":"Bischof J, Hierl M, Koller U. Emerging gene therapeutics for epidermolysis bullosa under development. Int J Mol Sci. 2024;25(4):2243.","journal-title":"Int J Mol Sci"},{"issue":"3","key":"2285_CR15","doi-asserted-by":"publisher","first-page":"164","DOI":"10.1016\/j.jdermsci.2021.11.004","volume":"104","author":"K Natsuga","year":"2021","unstructured":"Natsuga K, Shinkuma S, Hsu CK, Fujita Y, Ishiko A, Tamai K, et al. Current topics in epidermolysis bullosa: Pathophysiology and therapeutic challenges. J Dermatol Sci. 2021;104(3):164\u201376.","journal-title":"J Dermatol Sci"},{"issue":"3","key":"2285_CR16","doi-asserted-by":"publisher","first-page":"778","DOI":"10.1016\/j.jid.2016.10.038","volume":"137","author":"JW Bauer","year":"2017","unstructured":"Bauer JW, Koller J, Murauer EM, De Rosa L, Enzo E, Carulli S, et al. Closure of a large chronic wound through transplantation of gene-corrected epidermal stem cells. J Invest Dermatol. 2017;137(3):778\u201381.","journal-title":"J Invest Dermatol"},{"issue":"12","key":"2285_CR17","doi-asserted-by":"publisher","first-page":"1397","DOI":"10.1038\/nm1504","volume":"12","author":"F Mavilio","year":"2006","unstructured":"Mavilio F, Pellegrini G, Ferrari S, Di Nunzio F, Di Iorio E, Recchia A, et al. Correction of junctional epidermolysis bullosa by transplantation of genetically modified epidermal stem cells. Nat Med. 2006;12(12):1397\u2013402.","journal-title":"Nat Med"},{"issue":"1","key":"2285_CR18","doi-asserted-by":"publisher","DOI":"10.1186\/s13023-022-02546-9","volume":"17","author":"JY So","year":"2022","unstructured":"So JY, Nazaroff J, Iwummadu CV, Harris N, Gorell ES, Fulchand S, et al. Long-term safety and efficacy of gene-corrected autologous keratinocyte grafts for recessive dystrophic epidermolysis bullosa. Orphanet J Rare Dis. 2022;17(1):377.","journal-title":"Orphanet J Rare Dis"},{"issue":"24","key":"2285_CR19","doi-asserted-by":"publisher","first-page":"2211","DOI":"10.1056\/NEJMoa2206663","volume":"387","author":"SV Guide","year":"2022","unstructured":"Guide SV, Gonzalez ME, Ba\u011fc\u0131 IS, Agostini B, Chen H, Feeney G, et al. Trial of beremagene geperpavec (B-VEC) for dystrophic epidermolysis bullosa. N Engl J Med. 2022;387(24):2211\u20139.","journal-title":"N Engl J Med"},{"issue":"4","key":"2285_CR20","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1007\/s40257-025-00956-6","volume":"26","author":"MP Marinkovich","year":"2025","unstructured":"Marinkovich MP, Paller AS, Guide SV, Gonzalez ME, Lucky AW, Ba\u011fc\u0131 IS, et al. Correction to: Long-term safety and tolerability of beremagene geperpavec-svdt (B-VEC) in an open-label extension study of patients with dystrophic epidermolysis bullosa. Am J Clin Dermatol. 2025;26(4):637.","journal-title":"Am J Clin Dermatol"},{"issue":"6","key":"2285_CR21","doi-asserted-by":"publisher","first-page":"1116","DOI":"10.1016\/j.jid.2016.02.002","volume":"136","author":"T K\u00fchl","year":"2016","unstructured":"K\u00fchl T, Mezger M, Hausser I, Guey LT, Handgretinger R, Bruckner-Tuderman L, et al. Collagen VII half-life at the dermal-epidermal junction zone: implications for mechanisms and therapy of genodermatoses. J Invest Dermatol. 2016;136(6):1116\u201323.","journal-title":"J Invest Dermatol"},{"issue":"2","key":"2285_CR22","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1007\/s40291-024-00696-z","volume":"28","author":"SM Hoy","year":"2024","unstructured":"Hoy SM. Exagamglogene autotemcel: first approval. Mol Diagn Ther. 2024;28(2):133\u20139.","journal-title":"Mol Diagn Ther"},{"issue":"1","key":"2285_CR23","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-023-01309-7","volume":"8","author":"T Li","year":"2023","unstructured":"Li T, Yang Y, Qi H, Cui W, Zhang L, Fu X, et al. CRISPR\/Cas9 therapeutics: progress and prospects. Signal Transduct Target Ther. 2023;8(1):36.","journal-title":"Signal Transduct Target Ther"},{"issue":"6","key":"2285_CR24","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1016\/j.ymthe.2021.02.019","volume":"29","author":"J Bonafont","year":"2021","unstructured":"Bonafont J, Menc\u00eda A, Chac\u00f3n-Solano E, Srifa W, Vaidyanathan S, Romano R, et al. Correction of recessive dystrophic epidermolysis bullosa by homology-directed repair-mediated genome editing. Mol Ther. 2021;29(6):2008\u201318.","journal-title":"Mol Ther"},{"key":"2285_CR25","doi-asserted-by":"publisher","first-page":"16014","DOI":"10.1038\/npjregenmed.2016.14","volume":"1","author":"BR Webber","year":"2016","unstructured":"Webber BR, Osborn MJ, McElroy AN, Twaroski K, Lonetree CL, DeFeo AP, et al. CRISPR\/Cas9-based genetic correction for recessive dystrophic epidermolysis bullosa. NPJ Regen Med. 2016;1:16014.","journal-title":"NPJ Regen Med"},{"issue":"6","key":"2285_CR26","doi-asserted-by":"publisher","first-page":"1161","DOI":"10.1111\/bjd.19503","volume":"184","author":"CL Ebens","year":"2021","unstructured":"Ebens CL, McGrath JA, Riedl JA, Keith AR, Lilja G, Rusch S, et al. Immune tolerance of allogeneic haematopoietic cell transplantation supports donor epidermal grafting of recessive dystrophic epidermolysis bullosa chronic wounds. Br J Dermatol. 2021;184(6):1161\u20139.","journal-title":"Br J Dermatol"},{"issue":"4","key":"2285_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/bioengineering10040422","volume":"10","author":"A Niti","year":"2023","unstructured":"Niti A, Koliakos G, Michopoulou A. Stem cell therapies for epidermolysis bullosa treatment. Bioengineering. 2023;10(4):422.","journal-title":"Bioengineering"},{"issue":"6213","key":"2285_CR28","doi-asserted-by":"publisher","DOI":"10.1126\/science.1258096","volume":"346","author":"JA Doudna","year":"2014","unstructured":"Doudna JA, Charpentier E. Genome editing. The new frontier of genome engineering with CRISPR-Cas9. Science. 2014;346(6213):1258096.","journal-title":"Science"},{"issue":"3","key":"2285_CR29","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/s12033-022-00567-0","volume":"65","author":"VE Hillary","year":"2023","unstructured":"Hillary VE, Ceasar SA. A review on the mechanism and applications of CRISPR\/Cas9\/Cas12\/Cas13\/Cas14 proteins utilized for genome engineering. Mol Biotechnol. 2023;65(3):311\u201325.","journal-title":"Mol Biotechnol"},{"issue":"7","key":"2285_CR30","doi-asserted-by":"publisher","first-page":"639","DOI":"10.1016\/j.tig.2021.02.008","volume":"37","author":"C Xue","year":"2021","unstructured":"Xue C, Greene EC. DNA repair pathway choices in CRISPR-Cas9-mediated genome editing. Trends Genet. 2021;37(7):639\u201356.","journal-title":"Trends Genet"},{"issue":"1","key":"2285_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-41829-y","volume":"14","author":"L Zhao","year":"2023","unstructured":"Zhao L, Koseki SRT, Silverstein RA, Amrani N, Peng C, Kramme C, et al. PAM-flexible genome editing with an engineered chimeric Cas9. Nat Commun. 2023;14(1):6175.","journal-title":"Nat Commun"},{"issue":"1","key":"2285_CR32","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1016\/j.bj.2019.10.005","volume":"43","author":"B Paul","year":"2020","unstructured":"Paul B, Montoya G. CRISPR-Cas12a: functional overview and applications. Biomed J. 2020;43(1):8\u201317.","journal-title":"Biomed J"},{"issue":"2","key":"2285_CR33","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1016\/j.molcel.2021.12.026","volume":"82","author":"TS Nambiar","year":"2022","unstructured":"Nambiar TS, Baudrier L, Billon P, Ciccia A. CRISPR-based genome editing through the lens of DNA repair. Mol Cell. 2022;82(2):348\u201388.","journal-title":"Mol Cell"},{"issue":"5","key":"2285_CR34","doi-asserted-by":"publisher","first-page":"986","DOI":"10.1016\/j.ymthe.2019.03.007","volume":"27","author":"J Bonafont","year":"2019","unstructured":"Bonafont J, Menc\u00eda \u00c1, Garc\u00eda M, Torres R, Rodr\u00edguez S, Carretero M, et al. Clinically relevant correction of recessive dystrophic epidermolysis bullosa by dual sgRNA CRISPR\/Cas9-mediated gene editing. Mol Ther. 2019;27(5):986\u201398.","journal-title":"Mol Ther"},{"issue":"4","key":"2285_CR35","doi-asserted-by":"publisher","DOI":"10.1002\/btm2.10640","volume":"9","author":"A du Rand","year":"2024","unstructured":"du Rand A, Hunt J, Samson C, Loef E, Malhi C, Meidinger S, et al. Highly efficient CRISPR\/Cas9-mediated exon skipping for recessive dystrophic epidermolysis bullosa. Bioeng Transl Med. 2024;9(4):e10640.","journal-title":"Bioeng Transl Med."},{"issue":"10","key":"2285_CR36","doi-asserted-by":"publisher","first-page":"1985","DOI":"10.1016\/j.jid.2020.02.012","volume":"140","author":"T Kocher","year":"2020","unstructured":"Kocher T, March OP, Bischof J, Liemberger B, Hainzl S, Klausegger A, et al. Predictable CRISPR\/Cas9-mediated COL7A1 reframing for dystrophic epidermolysis bullosa. J Invest Dermatol. 2020;140(10):1985-1993.e5.","journal-title":"J Invest Dermatol"},{"issue":"8","key":"2285_CR37","doi-asserted-by":"publisher","first-page":"1711","DOI":"10.1016\/j.jid.2019.02.015","volume":"139","author":"S Takashima","year":"2019","unstructured":"Takashima S, Shinkuma S, Fujita Y, Nomura T, Ujiie H, Natsuga K, et al. Efficient gene reframing therapy for recessive dystrophic epidermolysis bullosa with CRISPR\/Cas9. J Invest Dermatol. 2019;139(8):1711-1721.e4.","journal-title":"J Invest Dermatol"},{"issue":"4","key":"2285_CR38","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1038\/nmeth.2857","volume":"11","author":"B Shen","year":"2014","unstructured":"Shen B, Zhang W, Zhang J, Zhou J, Wang J, Chen L, et al. Efficient genome modification by CRISPR-Cas9 nickase with minimal off-target effects. Nat Methods. 2014;11(4):399\u2013402.","journal-title":"Nat Methods"},{"issue":"1","key":"2285_CR39","doi-asserted-by":"publisher","first-page":"19482","DOI":"10.1038\/s41598-021-98965-y","volume":"11","author":"MS Schubert","year":"2021","unstructured":"Schubert MS, Thommandru B, Woodley J, Turk R, Yan S, Kurgan G, et al. Optimized design parameters for CRISPR Cas9 and Cas12a homology-directed repair. Sci Rep. 2021;11(1):19482.","journal-title":"Sci Rep"},{"issue":"5","key":"2285_CR40","doi-asserted-by":"publisher","first-page":"1298","DOI":"10.1016\/j.ymthe.2024.03.006","volume":"32","author":"J Klermund","year":"2024","unstructured":"Klermund J, Rhiel M, Kocher T, Chmielewski KO, Bischof J, Andrieux G, et al. On- and off-target effects of paired CRISPR-Cas nickase in primary human cells. Mol Ther. 2024;32(5):1298\u2013310.","journal-title":"Mol Ther"},{"issue":"7785","key":"2285_CR41","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1038\/s41586-019-1711-4","volume":"576","author":"AV Anzalone","year":"2019","unstructured":"Anzalone AV, Randolph PB, Davis JR, Sousa AA, Koblan LW, Levy JM, et al. Search-and-replace genome editing without double-strand breaks or donor DNA. Nature. 2019;576(7785):149\u201357.","journal-title":"Nature"},{"issue":"7603","key":"2285_CR42","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1038\/nature17946","volume":"533","author":"AC Komor","year":"2016","unstructured":"Komor AC, Kim YB, Packer MS, Zuris JA, Liu DR. Programmable editing of a target base in genomic DNA without double-stranded DNA cleavage. Nature. 2016;533(7603):420\u20134.","journal-title":"Nature"},{"key":"2285_CR43","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2024.1364135","volume":"15","author":"F Xu","year":"2024","unstructured":"Xu F, Zheng C, Xu W, Zhang S, Liu S, Chen X, et al. Breaking genetic shackles: the advance of base editing in genetic disorder treatment. Front Pharmacol. 2024;15:1364135.","journal-title":"Front Pharmacol"},{"issue":"3","key":"2285_CR44","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1038\/s41576-022-00541-1","volume":"24","author":"PJ Chen","year":"2023","unstructured":"Chen PJ, Liu DR. Prime editing for precise and highly versatile genome manipulation. Nat Rev Genet. 2023;24(3):161\u201377.","journal-title":"Nat Rev Genet"},{"issue":"11","key":"2285_CR45","doi-asserted-by":"publisher","first-page":"2573","DOI":"10.1016\/j.ymthe.2017.07.005","volume":"25","author":"S Hainzl","year":"2017","unstructured":"Hainzl S, Peking P, Kocher T, Murauer EM, Larcher F, Del Rio M, et al. COL7A1 editing via CRISPR\/Cas9 in recessive dystrophic epidermolysis bullosa. Mol Ther. 2017;25(11):2573\u201384.","journal-title":"Mol Ther"},{"issue":"11","key":"2285_CR46","doi-asserted-by":"publisher","first-page":"2585","DOI":"10.1016\/j.ymthe.2017.08.015","volume":"25","author":"T Kocher","year":"2017","unstructured":"Kocher T, Peking P, Klausegger A, Murauer EM, Hofbauer JP, Wally V, et al. Cut and paste: efficient homology-directed repair of a dominant negative KRT14 mutation via CRISPR\/Cas9 nickases. Mol Ther. 2017;25(11):2585\u201398.","journal-title":"Mol Ther"},{"issue":"11","key":"2285_CR47","doi-asserted-by":"publisher","first-page":"2592","DOI":"10.1016\/j.ymthe.2018.07.024","volume":"26","author":"D Benati","year":"2018","unstructured":"Benati D, Miselli F, Cocchiarella F, Patrizi C, Carretero M, Baldassarri S, et al. CRISPR\/Cas9-mediated in situ correction of LAMB3 gene in keratinocytes derived from a junctional epidermolysis bullosa patient. Mol Ther. 2018;26(11):2592\u2013603.","journal-title":"Mol Ther"},{"key":"2285_CR48","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1016\/j.omtn.2018.06.008","volume":"12","author":"A Izmiryan","year":"2018","unstructured":"Izmiryan A, Ganier C, Bovolenta M, Schmitt A, Mavilio F, Hovnanian A. Ex vivo COL7A1 correction for recessive dystrophic epidermolysis bullosa using CRISPR\/Cas9 and homology-directed repair. Mol Ther Nucleic Acids. 2018;12:554\u201367.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"52","key":"2285_CR49","doi-asserted-by":"publisher","first-page":"26846","DOI":"10.1073\/pnas.1907081116","volume":"116","author":"J Jack\u00f3w","year":"2019","unstructured":"Jack\u00f3w J, Guo Z, Hansen C, Abaci HE, Doucet YS, Shin JU, et al. CRISPR\/Cas9-based targeted genome editing for correction of recessive dystrophic epidermolysis bullosa using iPS cells. Proc Natl Acad Sci U S A. 2019;116(52):26846\u201352.","journal-title":"Proc Natl Acad Sci U S A"},{"key":"2285_CR50","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1016\/j.omtn.2019.09.011","volume":"18","author":"T Kocher","year":"2019","unstructured":"Kocher T, Wagner RN, Klausegger A, Guttmann-Gruber C, Hainzl S, Bauer JW, et al. Improved double-nicking strategies for COL7A1-editing by homologous recombination. Mol Ther Nucleic Acids. 2019;18:496\u2013507.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"3","key":"2285_CR51","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1016\/j.jdermsci.2020.04.004","volume":"98","author":"M Itoh","year":"2020","unstructured":"Itoh M, Kawagoe S, Tamai K, Nakagawa H, Asahina A, Okano HJ. Footprint-free gene mutation correction in induced pluripotent stem cell (iPSC) derived from recessive dystrophic epidermolysis bullosa (RDEB) using the CRISPR\/Cas9 and piggyBac transposon system. J Dermatol Sci. 2020;98(3):163\u201372.","journal-title":"J Dermatol Sci"},{"key":"2285_CR52","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1016\/j.omtn.2021.05.015","volume":"25","author":"T Kocher","year":"2021","unstructured":"Kocher T, Bischof J, Haas SA, March OP, Liemberger B, Hainzl S, et al. A non-viral and selection-free COL7A1 HDR approach with improved safety profile for dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids. 2021;25:237\u201350.","journal-title":"Mol Ther Nucleic Acids."},{"key":"2285_CR53","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2022.976604","volume":"9","author":"I Petkovi\u0107","year":"2022","unstructured":"Petkovi\u0107 I, Bischof J, Kocher T, March OP, Liemberger B, Hainzl S, et al. COL17A1 editing via homology-directed repair in junctional epidermolysis bullosa. Front Med (Lausanne). 2022;9:976604.","journal-title":"Front Med (Lausanne)."},{"issue":"6","key":"2285_CR54","doi-asserted-by":"publisher","first-page":"1322","DOI":"10.1016\/j.jid.2023.10.035","volume":"144","author":"C Berthault","year":"2024","unstructured":"Berthault C, Gaucher S, Gouin O, Schmitt A, Chen M, Woodley D, et al. Highly efficient ex vivo correction of COL7A1 through ribonucleoprotein-based CRISPR\/Cas9 and homology-directed repair to treat recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2024;144(6):1322-1333.e13.","journal-title":"J Invest Dermatol"},{"key":"2285_CR55","volume":"3","author":"A du Rand","year":"2024","unstructured":"du Rand A, Hunt J, Verdon D, Buttle B, Dunbar R, Purvis D, et al. Efficient dual Cas9 nickase correction of a prevalent pathogenic LAMB3 variant for junctional epidermolysis bullosa. JID Innov. 2024;3:100343.","journal-title":"JID Innov."},{"key":"2285_CR56","doi-asserted-by":"publisher","first-page":"5834","DOI":"10.1038\/s41467-024-49400-z","volume":"15","author":"G Neumayer","year":"2024","unstructured":"Neumayer G, Torkelson JL, Li S, McCarthy K, Zhen HH, Vangipuram M, et al. A scalable, GMP-compatible, autologous organotypic cell therapy for dystrophic epidermolysis bullosa. Nat commun. 2024;15:5834.","journal-title":"Nat commun"},{"key":"2285_CR57","doi-asserted-by":"publisher","DOI":"10.1016\/j.omtn.2025.102472","volume":"36","author":"JMT Hunt","year":"2025","unstructured":"Hunt JMT, du Rand A, Verdon D, Clemance L, Loef E, Malhi C, et al. Enhanced HDR-mediated correction of heterozygous COL7A1 mutations for recessive dystrophic epidermolysis bullosa. Mol Ther Nucleic Acids. 2025;36:102472.","journal-title":"Mol Ther Nucleic Acids."},{"issue":"20","key":"2285_CR58","doi-asserted-by":"publisher","first-page":"5676","DOI":"10.1073\/pnas.1512028113","volume":"113","author":"S Shinkuma","year":"2016","unstructured":"Shinkuma S, Guo Z, Christiano AM. Site-specific genome editing for correction of induced pluripotent stem cells derived from dominant dystrophic epidermolysis bullosa. Proc Natl Acad Sci U S A. 2016;113(20):5676\u201381.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"4","key":"2285_CR59","doi-asserted-by":"publisher","first-page":"586","DOI":"10.1089\/crispr.2021.0132","volume":"5","author":"M Bchetnia","year":"2022","unstructured":"Bchetnia M, Dionne Gagn\u00e9 R, Powell J, Morin C, McCuaig C, Dup\u00e9r\u00e9e A, et al. Allele-Specific Inactivation of an Autosomal Dominant Epidermolysis Bullosa Simplex Mutation Using CRISPR-Cas9. CRISPR J. 2022;5(4):586\u201397.","journal-title":"CRISPR J."},{"issue":"2","key":"2285_CR60","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.ymthe.2023.11.027","volume":"32","author":"C Cattaneo","year":"2024","unstructured":"Cattaneo C, Enzo E, De Rosa L, Sercia L, Consiglio F, Forcato M, et al. Allele-specific CRISPR-Cas9 editing of dominant epidermolysis bullosa simplex in human epidermal stem cells. Mol Ther. 2024;32(2):372\u201383.","journal-title":"Mol Ther"},{"issue":"8","key":"2285_CR61","doi-asserted-by":"publisher","first-page":"2680","DOI":"10.1016\/j.ymthe.2022.04.020","volume":"30","author":"J Bischof","year":"2022","unstructured":"Bischof J, March OP, Liemberger B, Haas SA, Hainzl S, Petkovi\u0107 I, et al. Paired nicking-mediated COL17A1 reframing for junctional epidermolysis bullosa. Mol Ther. 2022;30(8):2680\u201392.","journal-title":"Mol Ther"},{"issue":"7","key":"2285_CR62","doi-asserted-by":"publisher","first-page":"1660","DOI":"10.1073\/pnas.1614775114","volume":"114","author":"W Wu","year":"2017","unstructured":"Wu W, Lu Z, Li F, Wang W, Qian N, Duan J, et al. Efficient in vivo gene editing using ribonucleoproteins in skin stem cells of recessive dystrophic epidermolysis bullosa mouse model. Proc Natl Acad Sci U S A. 2017;114(7):1660\u20135.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"17\u201318","key":"2285_CR63","doi-asserted-by":"publisher","first-page":"1211","DOI":"10.1089\/hum.2024.238","volume":"36","author":"S L\u00f3pez-Manzaneda","year":"2025","unstructured":"L\u00f3pez-Manzaneda S, Menc\u00eda \u00c1, Bonafont J, Bassons-Bascu\u00f1ana A, Garc\u00eda M, Nystr\u00f6m A, et al. Safe and efficacious permanent removal of large COL7A1 exons for gene reframing as a reliable therapeutic strategy for recessive dystrophic epidermolysis bullosa. Hum Gene Ther. 2025;36(17\u201318):1211\u201321.","journal-title":"Hum Gene Ther."},{"issue":"12","key":"2285_CR64","doi-asserted-by":"publisher","first-page":"2764","DOI":"10.1016\/j.jid.2024.04.013","volume":"144","author":"BJ Steinbeck","year":"2024","unstructured":"Steinbeck BJ, Gao XD, McElroy AN, Pandey S, Doman JL, Riddle MJ, et al. Twin prime editing mediated exon skipping\/reinsertion for restored collagen VII expression in recessive dystrophic epidermolysis bullosa. J Invest Dermatol. 2024;144(12):2764-2777.e9.","journal-title":"J Invest Dermatol."},{"issue":"25","key":"2285_CR65","first-page":"00929","volume":"S1525\u20130016","author":"M Hierl","year":"2025","unstructured":"Hierl M, Bischof J, Liemberger B, Kocher T, Hainzl S, Gruner S, et al. Prime editing as a promising therapeutic strategy for junctional epidermolysis bullosa. Mol Ther. 2025;S1525\u20130016(25):00929\u201333.","journal-title":"Mol Ther"},{"issue":"8","key":"2285_CR66","doi-asserted-by":"publisher","first-page":"2664","DOI":"10.1016\/j.ymthe.2022.06.005","volume":"30","author":"SA Hong","year":"2022","unstructured":"Hong SA, Kim SE, Lee AY, Hwang GH, Kim JH, Iwata H, et al. Therapeutic base editing and prime editing of COL7A1 mutations in recessive dystrophic epidermolysis bullosa. Mol Ther. 2022;30(8):2664\u201379.","journal-title":"Mol Ther"},{"issue":"2","key":"2285_CR67","doi-asserted-by":"publisher","first-page":"338","DOI":"10.1016\/j.jid.2019.07.701","volume":"140","author":"MJ Osborn","year":"2020","unstructured":"Osborn MJ, Newby GA, McElroy AN, Knipping F, Nielsen SC, Riddle MJ, et al. Base Editor Correction of COL7A1 in Recessive Dystrophic Epidermolysis Bullosa Patient-Derived Fibroblasts and iPSCs. J Invest Dermatol. 2020;140(2):338-347.e5.","journal-title":"J Invest Dermatol"},{"issue":"1","key":"2285_CR68","doi-asserted-by":"publisher","first-page":"19643","DOI":"10.1038\/s41598-022-24184-8","volume":"12","author":"A Sheriff","year":"2022","unstructured":"Sheriff A, Guri I, Zebrowska P, Llopis-Hernandez V, Brooks IR, Tekkela S, et al. ABE8e adenine base editor precisely and efficiently corrects a recurrent COL7A1 nonsense mutation. Sci Rep. 2022;12(1):19643.","journal-title":"Sci Rep"},{"issue":"1","key":"2285_CR69","doi-asserted-by":"publisher","first-page":"e16","DOI":"10.1093\/bjd\/ljad174.029","volume":"189","author":"I Brooks","year":"2023","unstructured":"Brooks I, Rudnytska M, Gebrezgabher R, Laczmanski L, Newby G, Liu D, et al. P07 Optimizing DNA specificity and applicability of base and prime editors on COL7A1 variants causing recessive dystrophic epidermolysis bullosa. Br J Dermatol. 2023;189(1):e16\u20137.","journal-title":"Br J Dermatol"},{"key":"2285_CR70","doi-asserted-by":"crossref","unstructured":"\u200c Bassons-Bascu\u00f1ana A, Duarte B, M\u00e9ndez-Jim\u00e9nez E, Ugalde L, Sanabria-Betri\u00e1n P, Aussel C, et al. Base edited skin equivalents with clinical potential for ex vivo correction of Recessive Dystrophic Epidermolysis Bullosa. Mol Ther. 2025:S1525-0016(25)00962-1.","DOI":"10.1016\/j.ymthe.2025.11.023"},{"issue":"3","key":"2285_CR71","doi-asserted-by":"publisher","DOI":"10.1016\/j.xjidi.2023.100191","volume":"3","author":"G Naso","year":"2023","unstructured":"Naso G, Gkazi SA, Georgiadis C, Jayarajan V, Jack\u00f3w J, Fleck R, et al. Cytosine Deaminase Base Editing to Restore COL7A1 in Dystrophic Epidermolysis Bullosa Human: Murine Skin Model. JID Innov. 2023;3(3):100191.","journal-title":"JID Innov."},{"issue":"6","key":"2285_CR72","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1007\/s00439-023-02561-1","volume":"142","author":"JMT Hunt","year":"2023","unstructured":"Hunt JMT, Samson CA, du Rand A, Sheppard HM. Unintended CRISPR-Cas9 editing outcomes: a review of the detection and prevalence of structural variants generated by gene-editing in human cells. Hum Genet. 2023;142(6):705\u201320.","journal-title":"Hum Genet"},{"issue":"11","key":"2285_CR73","doi-asserted-by":"publisher","first-page":"1778","DOI":"10.1038\/s41587-024-02488-6","volume":"43","author":"G Cullot","year":"2024","unstructured":"Cullot G, Aird EJ, Schlapanksy MF, Yeh CD, van de Venn L, Vykhlyantseva I, et al. Genome editing with the HDR-enhancing DNA-PKcs inhibitor AZD7648 causes large-scale genomic alterations. Nat Biotchnol. 2024;43(11):1778\u201382.","journal-title":"Nat Biotchnol."},{"issue":"5","key":"2285_CR74","doi-asserted-by":"publisher","first-page":"1089","DOI":"10.1111\/j.1365-2133.2009.09333.x","volume":"161","author":"JS Kern","year":"2009","unstructured":"Kern JS, Gr\u00fcninger G, Imsak R, M\u00fcller ML, Schumann H, Kiritsi D, et al. Forty-two novel COL7A1 mutations and the role of a frequent single nucleotide polymorphism in the MMP1 promoter in modulation of disease severity in a large European dystrophic epidermolysis bullosa cohort. Br J Dermatol. 2009;161(5):1089\u201397.","journal-title":"Br J Dermatol"},{"issue":"1","key":"2285_CR75","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1111\/pde.12317","volume":"32","author":"A Schwieger-Briel","year":"2015","unstructured":"Schwieger-Briel A, Chakkittakandiyil A, Lara-Corrales I, Aujla N, Lane AT, Lucky AW, et al. Instrument for scoring clinical outcome of research for epidermolysis bullosa: a consensus-generated clinical research tool. Pediatr Dermatol. 2015;32(1):41\u201352.\u00a0","journal-title":"Pediatr Dermatol"},{"issue":"6","key":"2285_CR76","doi-asserted-by":"publisher","first-page":"1012","DOI":"10.1101\/gr.171322.113","volume":"24","author":"S Kim","year":"2014","unstructured":"Kim S, Kim D, Cho SW, Kim J, Kim JS. Highly efficient RNA-guided genome editing in human cells via delivery of purified Cas9 ribonucleoproteins. Genome Res. 2014;24(6):1012\u20139.","journal-title":"Genome Res"},{"issue":"3","key":"2285_CR77","doi-asserted-by":"publisher","first-page":"985","DOI":"10.1084\/jem.20171626","volume":"215","author":"A Seki","year":"2018","unstructured":"Seki A, Rutz S. Optimized RNP transfection for highly efficient CRISPR\/Cas9-mediated gene knockout in primary T cells. J Exp Med. 2018;215(3):985\u201397.","journal-title":"J Exp Med"},{"issue":"10","key":"2285_CR78","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1002\/humu.21551","volume":"32","author":"PC van den Akker","year":"2011","unstructured":"van den Akker PC, Jonkman MF, Rengaw T, Bruckner-Tuderman L, Has C, Bauer JW, et al. The international dystrophic epidermolysis bullosa patient registry: an online database of dystrophic epidermolysis bullosa patients and their COL7A1 mutations. Hum Mutat. 2011;32(10):1100\u20137.","journal-title":"Hum Mutat"},{"key":"2285_CR79","doi-asserted-by":"publisher","first-page":"17","DOI":"10.1016\/j.chembiol.2014.11.013","volume":"22","author":"M Srivastava","year":"2015","unstructured":"Srivastava M, Raghavan SC. DNA double-strand break repair inhibitors as cancer therapeutics. Chem Biol. 2015;22:17\u201329.","journal-title":"Chem Biol"},{"issue":"11","key":"2285_CR80","doi-asserted-by":"publisher","DOI":"10.1038\/mtna.2015.37","volume":"4","author":"XH Zhang","year":"2015","unstructured":"Zhang XH, Tee LY, Wang XG, Huang QS, Yang SH. Off-target effects in CRISPR\/Cas9-mediated genome engineering. Mol Ther Nucleic Acids. 2015;4(11):e264.","journal-title":"Mol Ther Nucleic Acids"},{"issue":"7","key":"2285_CR81","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22073326","volume":"22","author":"M Ablinger","year":"2021","unstructured":"Ablinger M, Lettner T, Friedl N, Potocki H, Palmetzhofer T, Koller U, et al. Personalized development of antisense oligonucleotides for exon skipping restores type XVII collagen expression in junctional epidermolysis bullosa. Int J Mol Sci. 2021;22(7):3326.","journal-title":"Int J Mol Sci"},{"issue":"22","key":"2285_CR82","doi-asserted-by":"publisher","first-page":"12222","DOI":"10.3390\/ijms222212222","volume":"22","author":"FC Vermeer","year":"2021","unstructured":"Vermeer FC, Bremer J, Sietsma RJ, Sandilands A, Hickerson RP, Bolling MC, et al. Therapeutic Prospects of Exon Skipping for Epidermolysis Bullosa. Int J Mol Sci. 2021;22(22):12222.","journal-title":"Int J Mol Sci"},{"issue":"7","key":"2285_CR83","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1038\/s41587-020-0453-z","volume":"38","author":"MF Richter","year":"2020","unstructured":"Richter MF, Zhao KT, Eton E, Lapinaite A, Newby GA, Thuronyi BW, et al. Phage-assisted evolution of an adenine base editor with improved Cas domain compatibility and activity. Nat Biotechnol. 2020;38(7):883\u201391.","journal-title":"Nat Biotechnol."},{"issue":"6","key":"2285_CR84","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1038\/s41587-023-01915-4","volume":"42","author":"M Fiumara","year":"2024","unstructured":"Fiumara M, Ferrari S, Omer-Javed A, Beretta S, Albano L, Canarutto D, et al. Genotoxic effects of base and prime editing in human hematopoietic stem cells. Nat Biotechnol. 2024;42(6):877\u201391.","journal-title":"Nat Biotechnol"},{"key":"2285_CR85","doi-asserted-by":"publisher","DOI":"10.1016\/j.copbio.2024.103071","volume":"86","author":"H Zeng","year":"2024","unstructured":"Zeng H, Daniel TC, Lingineni A, Chee K, Talloo K, Gao X. Recent advances in prime editing technologies and their promises for therapeutic applications. Curr Opin Biotechnol. 2024;86:103071.","journal-title":"Curr Opin Biotechnol"},{"issue":"6","key":"2285_CR86","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.1016\/j.stem.2021.02.002","volume":"28","author":"G Turchiano","year":"2021","unstructured":"Turchiano G, Andrieux G, Klermund J, Blattner G, Pennucci V, El Gaz M, et al. Quantitative evaluation of chromosomal rearrangements in gene-edited human stem cells by CAST-Seq. Cell Stem Cell. 2021;28(6):1136-1147.e5.","journal-title":"Cell Stem Cell"},{"issue":"1","key":"2285_CR87","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-42695-4","volume":"14","author":"Q Chen","year":"2023","unstructured":"Chen Q, Chuai G, Zhang H, Tang J, Duan L, Guan H, et al. Genome-wide CRISPR off-target prediction and optimization using RNA-DNA interaction fingerprints. Nat Commun. 2023;14(1):7521.","journal-title":"Nat Commun"},{"key":"2285_CR88","doi-asserted-by":"publisher","DOI":"10.3389\/fbioe.2023.1143157","volume":"11","author":"C Guo","year":"2023","unstructured":"Guo C, Ma X, Gao F, Guo Y. Off-target effects in CRISPR\/Cas9 gene editing. Front Bioeng Biotechnol. 2023;11:1143157.","journal-title":"Front Bioeng Biotechnol"},{"issue":"6","key":"2285_CR89","doi-asserted-by":"publisher","first-page":"2440","DOI":"10.1080\/03036758.2024.2347968","volume":"55","author":"C Samson","year":"2024","unstructured":"Samson C, du Rand A, Hunt J, Whitford W, Jacobsen J, Sheppard H. A bioinformatic analysis of gene editing off-target loci altered by common polymorphisms, using \u201cPopOff.\u201d J R Soc N Z. 2024;55(6):2440\u201363.","journal-title":"J R Soc N Z."},{"issue":"1","key":"2285_CR90","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1038\/s41588-022-01257-y","volume":"55","author":"S Cancellieri","year":"2023","unstructured":"Cancellieri S, Zeng J, Lin LY, Tognon M, Nguyen MA, Lin J, et al. Human genetic diversity alters off-target outcomes of therapeutic gene editing. Nat Genet. 2023;55(1):34\u201343.","journal-title":"Nat Genet"},{"issue":"8","key":"2285_CR91","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1038\/s41591-018-0137-0","volume":"24","author":"CA Vakulskas","year":"2018","unstructured":"Vakulskas CA, Dever DP, Rettig GR, Turk R, Jacobi AM, Collingwood MA, et al. A high-fidelity Cas9 mutant delivered as a ribonucleoprotein complex enables efficient gene editing in human hematopoietic stem and progenitor cells. Nat Med. 2018;24(8):1216\u201324.","journal-title":"Nat Med"},{"issue":"7-8","key":"2285_CR92","doi-asserted-by":"publisher","first-page":"396","DOI":"10.1038\/s41434-021-00263-9","volume":"28","author":"J Schofield","year":"2021","unstructured":"Schofield J, Harrison PT. Prime editing - an update on the field. Gene Ther. 2021;28(7\u20138):396\u2013401.","journal-title":"Gene Ther"},{"key":"2285_CR93","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1016\/j.omtm.2022.09.005","volume":"27","author":"M Garc\u00eda","year":"2022","unstructured":"Garc\u00eda M, Bonafont J, Mart\u00ednez-Palacios J, Xu R, Turchiano G, Svensson S, et al. Preclinical model for phenotypic correction of dystrophic epidermolysis bullosa by in vivo CRISPR-Cas9 delivery using adenoviral vectors. Mol Ther Methods Clin Dev. 2022;27:96\u2013108.","journal-title":"Mol Ther Methods Clin Dev."},{"key":"2285_CR94","doi-asserted-by":"crossref","unstructured":"Zeng M, Xu Q, Zhou D, AS, Alshehri F, Lara-S\u00e1ez I, et al. Highly branched poly(\u03b2-amino ester)s for gene delivery in hereditary skin diseases. Adv Drug Deliv Rev. 2021;176:113842.","DOI":"10.1016\/j.addr.2021.113842"},{"issue":"6","key":"2285_CR95","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.1600102","volume":"2","author":"D Zhou","year":"2016","unstructured":"Zhou D, Cutlar L, Gao Y, Wang W, O\u2019Keeffe-Ahern J, McMahon S, et al. The transition from linear to highly branched poly(\u03b2-amino ester)s: Branching matters for gene delivery. Sci Adv. 2016;2(6):e1600102.","journal-title":"Sci Adv"},{"key":"2285_CR96","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1038\/s41434-021-00282-6","volume":"29","author":"J O\u2019Keeffe Ahern","year":"2021","unstructured":"O\u2019Keeffe Ahern J, Lara-S\u00e1ez I, Zhou D, Murillas R, Bonafont J, Menc\u00eda \u00c1, et al. Non-viral delivery of CRISPR\u2013Cas9 complexes for targeted gene editing via a polymer delivery system. Gene Ther. 2021;29:157\u201370.","journal-title":"Gene Ther"},{"key":"2285_CR97","doi-asserted-by":"crossref","unstructured":"\u200cWang X, Wang X, Li Y, AS, Qiu B, Bushmalyova A, et al. CRISPR-Cas9-based non-viral gene editing therapy for topical treatment of recessive dystrophic epidermolysis bullosa. Mol Ther Methods Clin Dev. 2023;31:101134.","DOI":"10.1016\/j.omtm.2023.101134"},{"issue":"5","key":"2285_CR98","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nmat4249","volume":"14","author":"C Chiappini","year":"2015","unstructured":"Chiappini C, De Rosa E, Martinez JO, Liu X, Steele J, Stevens MM, et al. Biodegradable silicon nanoneedles delivering nucleic acids intracellularly induce localized in vivo neovascularization. Nat Mater. 2015;14(5):532\u20139.","journal-title":"Nat Mater"},{"issue":"17","key":"2285_CR99","doi-asserted-by":"publisher","DOI":"10.1002\/adma.202414728","volume":"37","author":"SA Mustfa","year":"2025","unstructured":"Mustfa SA, Dimitrievska M, Wang C, Gu C, Sun N, Roma\u0144czuk K, et al. Porous silicon nanoneedles efficiently deliver adenine base editor to correct a recurrent pathogenic COL7A1 variant in recessive dystrophic epidermolysis bullosa. Adv Mater. 2025;37(17):e2414728.","journal-title":"Adv Mater"},{"issue":"5","key":"2285_CR100","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1038\/s41587-021-01133-w","volume":"40","author":"AV Anzalone","year":"2022","unstructured":"Anzalone AV, Gao XD, Podracky CJ, Nelson AT, Koblan LW, Raguram A, et al. Programmable deletion, replacement, integration and inversion of large DNA sequences with twin prime editing. Nat Biotechnol. 2022;40(5):731\u201340.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2285_CR101","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/s41587-023-01748-1","volume":"42","author":"GD Lampe","year":"2024","unstructured":"Lampe GD, King RT, Halpin-Healy TS, Klompe SE, Hogan MI, Vo PLH, et al. Targeted DNA integration in human cells without double-strand breaks using CRISPR-associated transposases. Nat Biotechnol. 2024;42(1):87\u201398.","journal-title":"Nat Biotechnol"},{"issue":"1","key":"2285_CR102","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1038\/s41551-024-01227-1","volume":"9","author":"S Pandey","year":"2025","unstructured":"Pandey S, Gao XD, Krasnow NA, McElroy A, Tao YA, Duby JE, et al. Efficient site-specific integration of large genes in mammalian cells via continuously evolved recombinases and prime editing. Nat Biomed Eng. 2025;9(1):22\u201339.","journal-title":"Nat Biomed Eng."},{"issue":"4","key":"2285_CR103","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1038\/s41587-022-01527-4","volume":"41","author":"MTN Yarnall","year":"2023","unstructured":"Yarnall MTN, Ioannidi EI, Schmitt-Ulms C, Krajeski RN, Lim J, Villiger L, et al. Drag-and-drop genome insertion of large sequences without double-strand DNA cleavage using CRISPR-directed integrases. Nat Biotechnol. 2023;41(4):500\u201312.","journal-title":"Nat Biotechnol"},{"issue":"6748","key":"2285_CR104","doi-asserted-by":"publisher","first-page":"eadt5199","DOI":"10.1126\/science.adt5199","volume":"388","author":"IP Witte","year":"2025","unstructured":"Witte IP, Lampe GD, Eitzinger S, Miller SM, Berrios KN, King RT, et al. Continuous evolution of CRISPR-associated transposases for efficient, RNA-programmed gene insertion into the human genome. Science. 2025;388(6748):eadt5199.","journal-title":"Science"}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-026-02285-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-026-02285-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,21]],"date-time":"2026-03-21T06:02:28Z","timestamp":1774072948000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-026-02285-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,23]]},"references-count":104,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["2285"],"URL":"https:\/\/doi.org\/10.1007\/s40265-026-02285-2","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,2,23]]},"assertion":[{"value":"10 May 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 February 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest or competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest\/Competing Interests"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of Data and Material"}},{"value":"Not applicable.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"HS: Conceptualization of the manuscript; review and editing of the manuscript. AdR: Wrote the manuscript. BB: Review and editing of the manuscript.\u00a0All co-authors have read and approve the final manuscript and agree to be accountable for the work.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authors\u2019 Contributions"}}]}}